Core Viewpoint - Jitu Express Global Limited has completed the issuance of zero-coupon secured convertible bonds maturing in 2033, with a total principal amount of HKD 4.65 billion [2] Group 1: Bond Issuance Details - The convertible bonds were issued on February 5, 2026, and are expected to be listed on the Hong Kong Stock Exchange on or around February 6, 2026 [2] - The net proceeds from the issuance are approximately HKD 4.596 billion, with 70% allocated for overseas business and technology upgrades [2] - The joint global coordinators and joint bookrunners for the issuance are Morgan Stanley, BofA Securities, and J.P. Morgan [2] Group 2: Fund Allocation - Of the net proceeds, 60% will be used for upgrading overseas sorting centers, expanding trunk transportation capacity, and transitioning to green operations [2] - 10% of the proceeds will be allocated for upgrading the self-designed JMS system [2] - 20% will be used to optimize the capital structure, with authorization to repurchase up to approximately 890 million Class B ordinary shares, totaling no more than HKD 1 billion [2] - The remaining 10% will be used for general corporate purposes [2] Group 3: Share Dilution Impact - Based on the initial conversion price of HKD 14.55 per share, if all bonds are converted, approximately 320 million new shares will be issued, representing 3.47% of the enlarged share capital [2] - The shareholding percentage of founder Mr. Li Jie and his associates will be diluted from 11.01% to 10.62% [2]

Core Viewpoint - Hansoh Pharmaceutical (03692) announced the proposed issuance of HKD 4.68 billion zero-coupon convertible bonds maturing in 2033, with all conditions for the bond issuance having been met and successfully implemented on February 3, 2026 [1] Group 1 - The company has received approval for the listing and trading of the convertible bonds on the Hong Kong Stock Exchange [1] - The bonds are expected to be listed and traded on the Vienna MTF operated by the Vienna Stock Exchange on or around February 4, 2026 [1]

Group 1 - The company, China Ruyi (00136), announced the issuance of a zero-coupon convertible bond maturing in 2027, with a total principal amount of HKD 2.574 billion [1] - All conditions precedent under the subscription agreement have been fulfilled, and the bond issuance was completed on February 2, 2026 [1]

Core Viewpoint - Hansoh Pharmaceutical (03692) has experienced a decline of over 5%, currently trading at HKD 38.48, with a transaction volume of HKD 69.45 million [1] Group 1: Financial Actions - The company announced a proposal to issue HKD 4.68 billion zero-coupon convertible bonds maturing in 2033, with a conversion price of HKD 57.39, representing a premium of approximately 42.62% over the previous trading day's closing price [1] - The expected net proceeds from the bond issuance are approximately HKD 4.64 billion [1] Group 2: Use of Proceeds - Approximately 65% of the proceeds will be allocated for drug research and development and licensing [1] - About 25% will be used for the construction of new research and development centers and production lines, as well as upgrading existing facilities [1] - The remaining 10% will be designated for working capital and other general corporate purposes [1]